bluebird bio, Inc. (BLUE) Insider Philip D. Gregory Sells 2,250 Shares
bluebird bio, Inc. (NASDAQ:BLUE) insider Philip D. Gregory sold 2,250 shares of the firm’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $172.54, for a total transaction of $388,215.00. Following the sale, the insider now owns 28,734 shares in the company, valued at $4,957,764.36. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.
bluebird bio, Inc. (NASDAQ:BLUE) traded up $0.35 during midday trading on Tuesday, hitting $162.65. 563,699 shares of the stock were exchanged, compared to its average volume of 825,313. bluebird bio, Inc. has a 12 month low of $60.95 and a 12 month high of $174.65.
bluebird bio (NASDAQ:BLUE) last posted its quarterly earnings data on Wednesday, November 1st. The biotechnology company reported ($1.73) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.68) by ($0.05). bluebird bio had a negative net margin of 883.18% and a negative return on equity of 28.79%. The business had revenue of $7.71 million during the quarter, compared to analyst estimates of $8.47 million. During the same quarter last year, the business earned ($2.07) earnings per share. bluebird bio’s revenue for the quarter was up 397.4% on a year-over-year basis. sell-side analysts predict that bluebird bio, Inc. will post -6.68 EPS for the current fiscal year.
Several analysts have commented on the stock. Canaccord Genuity assumed coverage on shares of bluebird bio in a report on Tuesday. They set a “buy” rating and a $202.00 target price on the stock. Maxim Group raised their target price on shares of bluebird bio from $170.00 to $200.00 and gave the stock a “buy” rating in a report on Thursday, November 30th. SunTrust Banks raised their target price on shares of bluebird bio from $108.00 to $163.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. Jefferies Group restated a “hold” rating and set a $130.00 target price on shares of bluebird bio in a report on Friday, November 3rd. Finally, Morgan Stanley upgraded shares of bluebird bio from an “underweight” rating to an “equal weight” rating in a report on Friday, November 3rd. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and fourteen have assigned a buy rating to the company. The stock presently has an average rating of “Buy” and a consensus price target of $137.57.
ILLEGAL ACTIVITY WARNING: “bluebird bio, Inc. (BLUE) Insider Philip D. Gregory Sells 2,250 Shares” was first posted by American Banking News and is owned by of American Banking News. If you are reading this story on another publication, it was copied illegally and reposted in violation of international trademark & copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2017/12/05/bluebird-bio-inc-blue-insider-philip-d-gregory-sells-2250-shares.html.
About bluebird bio
bluebird bio, Inc is a clinical-stage biotechnology company. The Company is focused on developing gene therapies for severe diseases and cancer. With its lentiviral-based gene therapy and gene editing capabilities, it has built an integrated product platform with various applications in these areas. The Company’s clinical programs in severe genetic diseases include its LentiGlobin product candidate to treat transfusion-dependent b-thalassemia and to treat severe sickle cell disease (SCD) and its Lenti-D product candidate to treat cerebral adrenoleukodystrophy (CALD).
Receive News & Ratings for bluebird bio Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio Inc. and related companies with MarketBeat.com's FREE daily email newsletter.